NeurovascularMedicine.com
MEDICAL DISCLAIMER:The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website.









Modified Rankin Scale


Learning objectives

  • Learning
  • Understand
  • Integrate
  • Reflect

Score Description

The modified Rankin scale (mRS), a clinician-reported measure of global disability, is widely applied for evaluating stroke patient outcomes and as an end point in randomized clinical trials. Multiple types of evidence support its validity and reliability. The reported data support the view that the mRS is a valuable instrument for assessing the impact of new stroke treatments. A useful document on how to Training, questions and scoring is available.

Modified Rankin Scale
0 No symptoms at all
1No significant disability despite symptoms; able to carry out all usual duties and activities
2Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
3Moderate disability; requiring some help, but able to walk without assistance
4Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
5Severe disability; bedridden, incontinent and requiring constant nursing care and attention
6 Dead
Assessing Clinical Outcome

A good clinical outcome is a measure of neurologic functional with a score of 0-2 on the modified Rankin scale assessed 90 days after treatment. This does not exclude clinically significant benefit in patients in whom an mRS score of 2 is not achieved.